# Treadwell Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/treadwell-therapeutics

- Industry: Pharmaceuticals
- Headquarters: New York, US
- Website: www.treadwelltx.com
- Total disclosed funding: $118M
- Latest round: Series B (Nov 18, 2021)
- Investors on record: 6

## About

Treadwell Therapeutics, Inc. is a biotechnology company focused on developing innovative oncology treatments. Its pipeline includes first-in-class therapies that address significant unmet needs in cancer care, emphasizing a science-first approach.Treadwell Therapeutics, Inc. specializes in the development of oncology therapeutics targeting significant gaps in cancer treatment. Founded by Mark Bray and Shane Burgess, the company is headquartered in New York, US. In November 2021, Treadwell raised USD 91.00 mn in Series B funding, co-led by 3W Fund Management and Sino Biopharmaceutical, with participation from multiple investors. This funding marked a pivotal moment for the company, strengthening its financial position for future endeavors.Treadwell Therapeutics specializes in the development of innovative oncology treatments, focusing on a pipeline of first-in-class therapies designed to address significant unmet needs in cancer care. The company's core offerings include small molecules, biologics, and T-cell receptor-based cell therapies, all developed using a science-first approach to target novel therapeutic interventions. These therapies aim to provide effective treatment options for patients facing cancers with limited existing solutions. Treadwell Therapeutics targets healthcare providers, cancer treatment centers, and hospitals, serving patients who require advanced and personalized cancer therapies. The company's products are primarily marketed in North America and Europe, aligning with regions that exhibit a high demand for novel oncology treatments and where clinical trials are actively conducted.Treadwell Therapeutics generates revenue through partnerships with healthcare institutions and biopharmaceutical companies, focusing on collaborative clinical trials and research initiatives. The company engages in B2B transactions with hospitals and cancer treatment centers, where its therapies are integrated into treatment protocols for patients. Revenue is structured around agreements for access to its clinical candidates and potentially through licensing arrangements for successful products. Specific pricing plans are tailored to reflect the nature of the partnerships and the complexity of the therapies involved, ensuring that healthcare providers have access to cutting-edge treatments as they become available. The firm’s innovative pipeline, which includes proprietary therapies, is expected to drive revenue as products advance through clinical development into market-ready treatments.Treadwell Therapeutics plans to use the USD 91.00 mn raised in Series B funding to further the development of its product candidates and to enhance its organizational capabilities across all functions, ensuring it has the necessary talent to support its mission. The company is focused on advancing its pipeline of therapies and aims to expand its market presence in North America and Europe. As part of its growth strategy, Treadwell is exploring opportunities to launch new products and is committed to enhancing its clinical trial activities to bring innovative solutions to patients in need.

## Funding rounds

- Series B, Nov 18, 2021, $91M — Sino Biopharmaceutical Limited, 3W Fund Management, Prosperous Alliance Investments, China Fortune Ocean, TIO Bioventures, Alpha Win Capital Limited
- Seed, Jan 13, 2020, $27M — TIO Bioventures

## Investors

- TIO Bioventures (https://capitalatlas.ai/funds/tio-bioventures) — Seed, Series B
- Sino Biopharmaceutical Limited — Series B
- 3W Fund Management — Series B
- Prosperous Alliance Investments — Series B
- China Fortune Ocean — Series B
- Alpha Win Capital Limited — Series B